CytomX Therapeutics Files 8-K
Ticker: CTMX · Form: 8-K · Filed: May 28, 2025 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | 8-K |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
CytomX filed a routine 8-K, no major news.
AI Summary
CytomX Therapeutics, Inc. filed an 8-K on May 28, 2025, reporting an event on May 27, 2025. The filing is categorized under 'Other Events' and does not specify any material agreements, asset acquisitions, or executive changes.
Why It Matters
This filing indicates a routine update or event for CytomX Therapeutics, Inc. that requires disclosure to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose any significant financial or operational changes.
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Registrant
- May 27, 2025 (date) — Date of earliest event reported
- May 28, 2025 (date) — Date of report
FAQ
What specific event triggered this 8-K filing for CytomX Therapeutics, Inc. on May 27, 2025?
The filing is categorized under 'Other Events' and does not specify the exact nature of the event.
Is there any new material agreement or transaction disclosed in this 8-K?
No, the filing does not detail any new material agreements or transactions.
Does this filing involve any executive changes or compensation adjustments?
The filing does not mention any changes related to executives or their compensation.
What is the principal executive office address for CytomX Therapeutics, Inc.?
The principal executive offices are located at 151 Oyster Point Blvd, Suite 400, South San Francisco, California, 94080.
What is the SEC file number for CytomX Therapeutics, Inc.?
The SEC file number for CytomX Therapeutics, Inc. is 001-37587.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding CytomX Therapeutics, Inc. (CTMX).